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Effects of oral calcitriol on bone mineral density in patients with
end-stage renal failure. Evolution of bone mineral density (BMD) at
various skeletal sites and the influence of calcitriol on BMD are still
poorly documented in patients with terminal renal failure. Using dual
photon absorptiometry, we investigated the changes in BMD at the
levels of lumbar spine, femoral neck and midfemoral shaft in 21 patients
with end-stage renal failure (ESRF) treated with calcitriol (mean dosage
SEM: 0.21 0.02 sg/day) and compared them to 25 patients with
ESRF but not treated with calcitriol (control group) over a period of
20.3 1.5 and 17,2 1.2 months, respectively. Lumbar spine BMD
increased by 7.7 3.2%/year in the treated group and decreased by 2.5
1.3%/year in the control group (P < 0.005). Femoral shaft BMD
increased more in treated than in control group (+ 6.7 2.3 vs. + 1.4
2.0%/year; P < 0.05) and femoral neck BMD remained stable. PTH
levels increased by 92 121 and 1033 254 pmollyear (P < 0.01) in the
treated group and the controls, respectively. Osteocalcin changes were
—2.7 3.7 and +20.1 11.7 pg/liter (P < 0.05) per year in the same
groups. These results indicate that low doses of oral calcitriol in
patients with end-stage renal failure were associated with an increase in
BMD at the levels of lumbar spine and femoral shaft, and with a
stabilization of serum PTH and osteocalcin concentrations.
Bone mass is a major determinant of the skeletal resistance to
fracture [1—3]. Several studies have evaluated bone mineral
density in patients under long-term dialysis. Either appendicu-
tar bone, mostly composed of cortical bone, or axial skeleton,
comprising a substantial proportion of trabecular bone, were
monitored with contrasting results [4—10]. This probably re-
flects various underlying pathological processes, different
lengths or types of dialysis programs, variable compliance with
dietary or pharmacological interventions, or preferential sensi-
tivity of cortical or trabecular bone to excess of PTH. In a
recent cross sectional study performed in 106 patients attending
the same dialysis center, we demonstrated, using dual photon
absorptiometry, a particularly marked decrease in bone mineral
density at the levels of lumbar spine, femoral neck and of a
cortical weight-bearing bone, the midfemoral shaft [10].
Osteodystrophy is a prominent feature in patients with ter-
minal renal failure undergoing dialysis therapy. Although van-
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ous histological forms of bone disease have been demonstrated
depending on dietary intakes, aluminum exposure, or dialysis-
related factors, osteitis fibrosa represents the most frequent
form, the severity of which appears to be proportional to the
degree of secondary hyperparathyroidism [11—15]. The treat-
ment of this form of renal osteodystrophy involves the control
of excess PTH. Over the last two decades, most studies (very
few were double-blind placebo-controlled) have provided evi-
dence for the beneficial effects of calcitniol on biochemical,
radiological and histological manifestations of hyperparathy-
roidism [16—22]. Indeed, calcitniol directly inhibits PTH secre-
tion [23], causing declines in PTH levels of greater magnitude
than those achieved with similar increases of calcemia. Further-
more, adequate suppression of PTH in uremia may require
high, potentially toxic plasma calcium levels.
Thus, if calcitriol therapy is largely recognized as exerting
favorable influence on osteodystrophy encountered in the frame
of end-stage renal failure, the effects of its chronic administra-
tion on bone mineral density of various skeletal sites particu-
larly prone to osteoporotic fractures, such as lumbar spine and
femoral neck, have not yet been clearly documented. In the
treatment of postmenopausal or senile osteoporosis, the effi-
cacy of calcitriol is still largely debated [24-27].
In the present study, we prospectively monitored the evolu-
tion of bone mineral density at the levels of lumbar spine,
femoral neck and midfemoral shaft in patients with end-stage
renal failure. The patients were divided into two groups, with or
without low doses of oral calcitriol. The results indicated that
oral calcitniol was associated with significant increases in lum-
bar spine and midfemoral shaft bone mineral density and with a
stabilization of serum PTH and osteocalcin concentrations.
Methods
Subjects
Bone mineral density (BMD) was prospectively assessed in
patients with end-stage renal failure attending the University
Hospital of Geneva dialysis center. The date of inclusion in the
study was the date of the first BMD measurement. To evaluate
the effects of oral calcitniol therapy on BMD and parathyroid
status, subjects were divided into two groups: one (N = 21)
which was receiving oral calcitniol (Rocaltrol®) at doses ranging
from 0.25 g thrice a week to 0.5 jg daily at the beginning of the
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study. The goal of this treatment, which lasted 3 to 24 months
in 16 patients, was to achieve a plasma calcium level averaging
2.30 to 2.50 mmollliter. In the control group (N = 25), preven-
tion of osteodystrophy was limited to oral phosphate binder
therapy. All patients had a second BMD measurement per-
formed 20.3 1.5 and 17.2 1.2 months later for the calcitriol-
treated and the control groups, respectively.
Phosphate binder therapy consisted of either aluminum hy-
droxide or calcium carbonate, or a combination of both agents;
the goal was to maintain plasma phosphate level lower than 2.0
mmollliter. All patients were advised to take the same phos-
phate-restncted diet. In controls, 17 patients were never given
calcitriol; in 8 patients, calcitriol had been discontinued more
than six months before the beginning of the study. The cessa-
tion of calcitriol therapy was justified only in two cases by
moderate hypercalcemia. We excluded one patient with multi-
ple myeloma in the treated group, and one of the controls who
underwent parathyroidectomy during the course of the study.
One patient in the control group had a subtotal parathyroidec-
tomy four years before the beginning of the study. Four patients
in each group had a renal transplant which was functional for
less than three months, at least two years before inclusion in the
study. Dialysis therapy was hemodialysis for three to four hours
thrice weekly in 27 patients, continuous ambulatory pentoneal
dialysis in 13 patients and both methods of dialysis successively
in four patients. Only two patients were still in pre-dialysis
stage during the course of the study.
Methods
Determinations of plasma calcium, phosphate and alkaline
phosphatase were performed monthly by atomic absorption
spectrophotometry and colorimetric methods, respectively.
Values represent the means of five monthly determinations
done around the time of each BMD measurement. Plasma
magnesium and aluminum were only assessed at the time of
BMD measurements. Determination of aluminum was per-
formed by flameless atomic absorption after appropriate dilu-
tion; magnesium was measured by atomic absorption spectro-
photometry. For plasma aluminum determination, results lower
than 1.2 moI/liter were given a value of 1.2 pmolJliter. To
detect aluminum overload, a deferoxamine test was done yearly
by infusing 40 mg/kg body wt at the end of a dialysis session
[28]. An increase in plasma aluminum higher than 5.6 rmol/liter
at 24 hours or 48 hours after deferoxamine administration was
considered as positive. In that case a course of deferoxamine
therapy was started (40 mg/kg body wtlweek for 6 months).
Serum PTH level was measured by radioimmunoassay using
antibodies directed against a mid molecule epitope (amino
acids: 44-68; Endocrine Metabolic Center; interassay coeffi-
cient of variation: 5.8 to 9%). During the course of the study,
the PTH assay changed and only 28 values were available at the
second BMD measurement to be compared with the first mid
molecule determinations. Serum osteocalcin level was mea-
sured by radioimmunoassay (Cis Oris, Gif sur Yvette, France;
interassay coefficient of variation: 6.6%).
Dual photon absorptiometry was performed using a Norland
2600 instrument at the levels of lumbar spine (L2—L4), midfem-
oral shaft and femoral neck. Coefficients of variation were
2.1%, 1.4% and 2.0% for lumbar spine, femoral shaft and
femoral neck BMD measurements, respectively [29]. The I Ci
Table 1. Patient characteristics
Group with
Control calcitriol
group therapyN=25 N=21
Age years 56.8 2.9 56.2 3.6
(Range) (22—74) (13—83)
Sex male/female 14/11 13/8
Menopause % 100 100
Underlying renal diseases:
Chronic glomerulonephritis 10 8
Nephrosclerosis 7 6
Interstitial nephritis 3 S
Polycystic kidney disease 2 2
Diabetic nephropathy 2 0
Reflux nephropathy 1 0
Dialysis duration before 32.1 8.2 48.9 10.2
the first BMD
assessment months
(Range) (0—141) (0—136)
Results are given as absolute numbers or as means SEM. There
were no significant differences between groups in any parameters using
the Mann Whitney test or chi-square test when appropriate.
'"Gd radioactive source was not older than nine months. For
the patients on continuous ambulatory peritoneal dialysis,
dialysate was drained out prior to lumbar spine BMD measure-
ments. X-ray was regularly performed to rule out compression
fractures during the follow-up period. Because the program to
analyze BMD at the level of femoral neck was not available at
the beginning of the study, this measurement was performed in
25 patients only (15 patients in control group and 10 patients in
group with calcitriol therapy). The results were expressed in
absolute values, in standard deviations from the mean of age-
and sex-matched normal subjects (Z-score), or in deviation in
percent from peak bone mass of young normal sex-matched
adults (% PBM) [30].
Statistical analysis
Values are means SEM. Mann-Whitney's test was used to
compare intergroup differences. Paired Student's t-test was
used to compare values in the same group between the first and
second BMD measurements. The chi-square test was used
where appropriate. Correlation was performed by Spearman
method. A P value (two tailed) < 0.05 was interpreted as
significant.
Results
Patient characteristics
The two groups were similar with respect to age, sex distri-
bution, menopausal status and prevalence of underlying renal
diseases (Table 1). Mean dialysis duration appeared to be longer
in the calcitriol-treated group but this difference was not statis-
tically significant. The dialysis parameters and the medical
treatment during the study are presented in Table 2. The mean
follow-up periods were similar in the two groups as were the
types of dialysis therapy and the mean dialysate calcium
concentrations. The mean daily dose of oral calcitriol was 0.21
0.02 p.g for the 21 treated patients. Mild to moderate
hypercalcemia (2.70 to 2.90 mmol/liter) occurred in four cases
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Table 2. Dialysis parameters and medical treatment
Group with
Control calcitriol
group therapyN=25 N=21
Mean follow-up period months 17.2 1.2 20.3 1.5
Type of dialysis therapy during the 13/9/1/2 14/4/3/0
study: HD/CAPD/mixed therapy!
no dialysis
Dialysate calcium concentration 1.70 0.03 1.71 0.02
for HD and CAPD patients
mmo!/liter
Number of patients with dialysate
calcium concentration of
1.75 mmol/liter 20 18
1.50 mmol!liter 1 3
1.25 mmol!liter 2 0
Daily dose of oral calcitriol .g/day 0 0.21 0.02
Type of phosphate binders therapy 6/2/8/4 5/6/5/1
(CaCO3!Al(OH)3/mixed/no
treatment)
Daily dose of phosphate binders
CaCO3 g!day 2.3 0.4 2.7 0.6
A1(OH)3 g!day 0.7 0.2 1.7 0.4k
Number of patients treated with 3 5
deferoxamine during the study
Results are given as absolute numbers or as means SEM. Abbrevi-
ations are: HD, hemodialysis; CAPD, continuous ambulatory perito-
neal dialysis. Differences between groups were evaluated using the
Mann-Whitney test or chi-square test when appropriate.
a P < 0.05 as compared with value in the control group
and necessitated the discontinuation of this therapy; neverthe-
less, duration of calcitnol therapy in these four patients was 61
11% of the mean follow-up period. The mean dose of
aluminum hydroxide was lower in the control group as com-
pared with the group on calcitriol therapy (0.7 0.2 vs. 1.7
0.2 gfday). The number of patients treated with deferoxamine
during the follow-up period were similar in the two groups (3
and 5 patients in controls and calcitriol-treated group, respec-
tively).
Evolution of biochemical variables
There was no significant difference in the plasma levels of
calcium, phosphate and magnesium measured at the beginning
and the end of the study, when all patients were analyzed
together (Table 3). An overall increase in alkaline phosphatase
was observed, but this was not significant when subjects who
developed transfusion-acquired hepatitis were excluded from
analysis (N = 8). PTH level was significantly higher at the end
of the study. The higher mean serum osteocalcin level at the
second BMD measurement did not reach statistical signifi-
cance. The small decrease in aluminum level may be due to the
preferential use of calcium carbonate rather than aluminum
hydroxide adopted during the course of the study and to
treatments of aluminum-overloaded patients with deferox-
amine. At the end of the study, only one patient had an
aluminum increment after deferoxamine loading greater than
5.6 molJliter. Both groups had a mean basal plasma aluminum
of 1.3 0.1 molJliter.
When comparing the control group with the group treated
with oral calcitriol, calcemia was lower at the start of study in
the latter, but the difference was no longer statistically signifi-
cant at the end of the follow-up. During the study, PTH levels
nearly doubled in the control group whereas the mean value
remained stable in the group treated with oral calcitriol. The
results for osteocalcin level displayed the same pattern, but the
increase of mean osteocalcin level in the control group did not
reach statistical significance. However, as depicted in Figure 1,
when expressed as percent change of initial value per year, the
calcitnol-treated group displayed increases in osteocalcin and
PTH levels of lower amplitudes than those of the control group
(osteocalcin: +2.1 8.2%/year vs. +43.9 22.4%/year; P <
0.05. PTH: +21.5 15.3%/year vs. + 129.7 51.2%/year; P <
0.05).
Evolution of bone mineral density
The initial BMD values of all patients, expressed in Z-score,
are presented on Table 4. Z-scores were significantly decreased
at the three skeletal sites (P < 0.01). They appeared to be more
severely depressed at the levels of femoral shaft (—1.19 0.20)
and femoral neck (—1.13 0.16) than that of lumbar spine
(—0.66 0.23), but differences were not statistically significant.
Except for femoral neck, initial values of BMD were signifi-
cantly lower in the group treated with calcitriol. Figures 2, 3 and
4 depict the evolution of individual BMD values of lumbar
spine, femoral shaft and femoral neck. At the level of lumbar
spine, we observed a significant increase in BMD in the group
treated with calcitriol (from 0.842 0.041 g/cm2 to 0.945
0.055 g/cm2; P < 0.01), whereas the mean value of BMD tended
to decrease (from 0.993 0.033 g/cm2 to 0.956 0.037 g/cm2;
P < 0.05) in the control group. At the midfemoral shaft level, a
similar pattern with a significant increase of the mean BMD in
the treated group (from 1.423 0.086 g/cm2 to 1.571 0.114
g/cm2; P < 0.01) and a stabilization in the control group (from
1.696 0.053 g/cm2 to 1.737 0.064 g/cm2) was observed. The
mean change in femoral neck BMD of neither the calcitriol-
treated group (from 0.685 0.046 g/cm2 to 0.72 1 0.041 glcm2)
nor the control group (from 0.742 0.035 g/cm2 to 0.726
0.027 g/cm2) reached statistical significance. For this skeletal
site only ten paired values could be analyzed in the treated
group. Figure 5 shows the variations in BMD given as percent
changes per year from baseline values. Calcitriol therapy was
associated with an increase in BMD at the levels of lumbar
spine (P < 0.005) and femoral shaft (P < 0.05). At the level of
femoral neck, the increment was less pronounced and not
significantly different from non-treated patients (+ 1.3 2.3%/
year in the group treated with calcitriol and —0.1 0.9%/year
in the control group). The same pattern of results was observed
when postmenopausal women were separately evaluated (data
not shown).
Since mean initial BMDs were lower in the treated group, we
intended to compare subjects with identical initial BMDs and
selected 12 pairs with matched initial lumbar spine values in
controls and treated patients (0.954 0.049 g/cm2 vs. 0.950
0.048 g/cm2). Over the study period, a gain in the calcitriol-
treated group (+8.0 2.5%/year) and a decrease in the control
group (—3.9 1.7%/year; P < 0.001) were observed. In these
pairs with matched initial lumbar spine BMD, PTH concentra-
tions increased from 1656 547 to 2521 970 in controls (P <
0.025), but remained stable in the calcitriol-treated group from
1402 275 to 1474 288 pmol/liter (NS). When pairs (N = 14)
with similar femoral shaft BMD were considered (1.611 0.061
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Table 3. Biochemical data
All patientsN=46 Control groupN=25
Group with cal
N=citriol therapy21
Ti 12 Ti 12 Ti T2
Plasma calcium mmollliter 2.39 0.02 2.38 0.02 2.44 0.02 2.41 0.03 2.34 0.02" 2.35 0.04
(2.25—2.60)
Plasma phosphate mmollliter 1.8 0.1 1.9 0.1 1.8 0.1 1.8 0.1 1.9 0.1 2.0 0.1
(0.8—1.3)
Plasma magnesium mmol/liter 0.99 0.04 1.00 0.03 1.02 0.06 1.04 0.04 0.96 0.05 0.95 0.04
(0.65—0.82)
Alkaline phosphatase U/liter 124 9 154 181) 112 8 135 12b 138 16 177 36
(30—125)
Alkalinephosphatase U/liter 112±7 119 108±8 120±10 117±14 118±9
(30—125), without hepatitis
N 38 38 22 22 16 16
Serum osteocalcin smol/liter 46.3 4.7 58.7 10.7 44.2 5.8 72.2 18,3 48.8 7.8 42.6 8.1
(3.0-13.5)
Serum PTHpmol/liter (60—135) 1653 256 2520 425° 1859 444 3377 713° 1417 208 1531 199°
N 43 28 23 15 20 13
Plasma alummum i.unol/lirer 1.6 0.1 1.3 0.1° 1.5 0.2 1.3 0.1 1.8 0.2 1.3 0.la
Number of patients with plasma 9 1 4 0 5 1
aluminum> 5.6 pinol/liter
Results are means SEM. Abbreviations are: TI, values at the time of first bone mineral density measurement; T2, values at the time of the
second bone mineral density measurement. For plasma calcium, phosphate and alkaline phosphatase, the mean was calculated with individual
results, which themselves represent the mean of 5 monthly determinations (around the time of each BMD measurement). The normal ranges are
in parentheses.
a p < 0.05, b p < 0.025, P < 0.01 T2 vs. Tl using paired t-testd P < 0.01 vs. control group for Ti using the Mann-Whitney test
e P = 0.06 vs. control group for T2 using the Mann-Whitney test
E
4)
C,)
N=25 N=21 N=15 N=12
Calcitrol — + — +
Fig. 1. Serum osteocalcin and PTH levels expressed in percent change
of initial values per year. Values are means SEM. Differences are
evaluated with a Mann-Whitney test. Symbols are: () control group;
() group with calcitriol therapy.
g/cm2 vs. 1.636 0.061 g/cm2), the evolution was similar to that
of the whole group with an increase in the treated group (+9.1
2.9%/year) of higher amplitude than that of the controls (+0.4
2.6%/year; P < 0.025). These pairs did not differ in age, sex
prevalence, type or duration of dialysis.
Over the whole study period only one fracture supervened
(femoral neck) in the control group; in this case, femoral neck
BMD Z-scores were —0.30 and —0.68 at the first and the second
measurements, respectively.
Discussion
In this controlled longitudinal study, low doses of calcitriol
appeared to exert a favorable influence on lumbar spine and
midfemoral shaft bone mineral density. This was associated
with a stabilization of serum PTH and osteocalcin concentra-
tions.
The pathogenesis of renal osteodystrophy is related, at least
in part, to elevated PTH levels in association with decreased
alcitriol production [11—15]. The relationship between hyper-
parathyroidism and bone mass has been reviewed recently, and
there is some evidence for a preferential decrease in cortical
bone induced by an excess of PTH [31, 32]. In the present
study, we confirmed the low bone mineral density at the levels
of midfemoral shaft and femoral neck in patients on dialysis.
However, we cannot be certain that elevated PTH concentra-
tion was a main contributor to the decreased bone mass. The
high prevalence of menopausal females should be emphasized,
since all were amenorrheic in our cohort. Low bone mass could
also be the reflection of impaired mineralization. Among the
possible causes, aluminum could be invoked. However, the
200
Osteocalcin PTH
100
(P.cO.05)
Ruedin et a!: Calcitriol and bone mineral density in CRF 249
Table 4. Bone mineral density values
All patientsN=46 Control groupN—255 Group with calcitriol therapyN=2l5
TI T2 TI T2TI T2
Lumbar spine
BMD glcm2 0.924 0.028 0.951 0.032 0.993 0.033 0.956 0.037 0.842 O.O4l 0.945 0.055C
Z-score —0.66 0.23 —0.39 0.27 —0.15 0.30 —0.38 0.33 —1.28 0.34e —0.42 0.46''
PBM % —16.4 2.4 —14.6 2.8 —10.7 2.9 —14.0 33a —23.1 34C —15.2 49
Femoral shaft
BMD g/cm2 1.572 0.052 1.662 0.063C 1.696 0.053 1.737 0.064 1.423 0.086e 1.571 0.Il4C
Z-score —1.19 0.20 —0.93 0.24 —0.75 0.21 —0.54 0.22 —1.72 O.32 —1.39 0.46
PBM % —18.8 2.2 —16.6 2.9 —14.2 2.5 —14.0 3.3 —24.4 35 —15.2 4.9
Femoral neck
BMD g/cm2 0.719 0.028 0.724 0.025 0.742 0.035 0.726 0.027 0.685 0.046 0.721 0.041
N 25 44 15 25 10 19
Z-score —1.13 0.16 —1.12 0.14 —0.90 0.24 —1.08 0.18 —1.47 o.Ise —1.19 0.25
N 25 44 15 25 10 19
PBM % —27.2 2.2 —28.0 2.2 —25.6 3.0 —27.4 2.5 —29.7 2.9 —28.9 3.8
N 25 44 15 25 10 19
Results are given as means SEM. Abbreviations are: Ti, values at the time of the first bone mineral density measurement; T2, values at the
time of the second bone mineral density measurement. Z-score represents the standard deviation from the mean of age- and sex-matched normal
subjects. PBM % represents the deviation from the peak bone mass of young normal sex-matched adults expressed in percent.
a p < 0.05, b p < 0.025, C p < 0.01 T2 vs. Ti using paired t-test
e p < 0.05, P = 0.025 group with calcitriol therapy vs. control group for Ti using the Mann-Whitney test
For lumbar spine and femoral shaft BMD measurements.
A B___________1.61.4
1.2
____
1.0 ::::...:::
0.8
0.6
E 0.4 (NS) (P<0.01)
Fig. 2. Individual values of lumbar spine
_______________________________
________________________________
bone mineral density in the control group (A)0.2 and in the group with calcitriol therapy (B).0 6 12 18 24 30 36 0 6 12 18 24 30 36 Differences are evaluated using a two-tailed
paired Student's-test. Symbol is: (—) mean
Duration of follow-up, months Duration of follow-up, months bone mineral density SCM.
'930A B___________
2.5k
_2.0
1.5
1.0
_________
0.5 Fig. 3. Individual values of midfemoral shaft(NS) (P<0.01) bone mineral density in the control group (A)00 '' and in the group with calcitriol therapy (B).0 6 12 18 24 30 36 0 6 12 18 24 30 36 Differences are evaluated using a two-tailed
paired Student's r-test. Symbol is: (—) mean
Duration of follow-up, months Duration of follow-up, months bone mineral density SCM.
influence of aluminum overload would be negligible, since the increases intestinal absorption of aluminum, this did not seem
use of phosphate chelators containing aluminum was progres- to have significant consequences in our patients [33].
sively replaced during the study period and since the prevalence The administration of calcitriol has been shown to reduce
of a positive deferoxamine test was low, at least similar in both PTH concentrations and to lead to an improvement of bone
groups of patients. Although it has been reported that calcitriol histological signs of secondary hyperparathyroidism in the
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FIg. 4. Individual values of femoral neck
bone mineral density in control group (A) and
in the group with calcitriol therapy (B).
Differences are evaluated using a two-tailed
paired Student's paired t-test. Symbol is:(—) mean bone mineral density SEM.
Fig. 5. Changes in bone mineral density, at
the levels of lumbar spine, femora! shaft and
femoral neck, expressed in percent change of
initial values per year. Values are means
SEM. Differences are evaluated with a Mann-
Whitney test. Symbols are: () control group;
(I) group with calcitriol therapy.
frame of chronic renal failure [15—22]. Calcitriol decreases
the proliferation rate of parathyroid epithelial cells, lowers the
synthesis and secretion of PTH, through the restoration of
the sensitivity of parathyroid cells to extracellular calcium
concentrations. It was thus of interest to assess the influence of
calcitriol on BMD of skeletal sites particularly prone to osteo-
porotic fractures, such as lumbar spine and femoral neck. Our
study was a longitudinal assessment of the evolution of BMD at
these skeletal sites. The patients were not randomly allocated to
calcitriol therapy or control groups, but the grouping was
performed retrospectively. Whereas phosphate chelators have
been routinely used, there was no uniform policy concerning
calcitriol therapy in our dialysis center. This could explain why
the two groups, which were determined retrospectively, did not
markedly differ. Furthermore, they were studied over the same
period of time ruling out temporal drift in BMD measurements.
Calcitriol therapy had been introduced before the first BMD
measurement, and was maintained throughout the study period.
This treatment was associated with increases in lumbar spine
and midfemoral shaft BMDs. The relatively small number of
measurements available and the variability of the BMD mea-
surements at the femoral neck level possibly prevented signif-
icant effects to be detected there.
Clinical or biochemical signs of impaired mineralization could
have constituted arguments for the prescription of calcitriol.
Indeed, not only initial plasma calcium concentrations, but also
lumbar spine and midfemoral shaft BMD values were slightly
lower in the calcitriol-treated group which had started treatment
well before BMD measurements. In contrast, alkaline phos-
phatase, osteocalcin, PTH and aluminum levels were not dif-
ferent between the two groups. Thus, to evaluate the effects of
calcitriol in patients with similar initial BMDs, we selected pairs
S
.-....
061218243036 061218243036
Duration of follow-up, months Duration of follow-up, months
(NS)I
Cl)C
a,V
Ce
a,C
E
0
1.2
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1.0
08
(NS)0.2
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12
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6
4
2
0
—2
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—6
N=25 N=21 N=25 N=21 N=15 N=10
Calcitrol — + — + — +
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in the calcitriol-treated and the control groups with matched
BMDs. This analysis indicates that the effects of calcitriol on
lumbar spine or midfemoral BMDs in patients with identical
initial BMDs were quite comparable to those found in the whole
cohort. This suggests that the positive influence of calcitriol
could not merely result from the correction of a subclinical
osteomalacic component.
The increases of BMD induced by calcitriol in patients with
end-stage renal failure contrasts with the effects of this drug in
postmenopausal osteoporosis, where they are much less evi-
dent [24—27]. Although we did not measure calcitriol concen-
trations in the present study, they are classically very low in
terminal renal failure, whereas they are mostly within the
normal range, though they might be slightly lower, in post-
menopausal osteoporosis [34]. Furthermore, elevated PTH is
not a uniform feature of this latter condition. Thus, one could
expect to see more dramatic effects of calcitriol therapy in
disease states characterized by a decreased level of this latter
hormone and elevated PTH.
The low doses of calcitriol administered were remarkably
well tolerated. Indeed, in only four cases was the treatment
discontinued because of moderate hypercalcemia. Similarly, we
did not detect any increase in plasma phosphate concentration,
nor were we obliged to increase phosphate binder therapy,
despite the fact that calcitriol is known to stimulate intestinal
absorption of phosphate [35].
As suggested for the prevention and treatment of osteitis
fibrosa, calcitriol could also be envisaged in the therapy of renal
failure-associated osteoporosis. This possibility should be sup-
ported by results obtained in randomized double-blind long-
term studies, which should assess whether positive influences
on bone mass will be associated with commensurate decrease in
fracture rates.
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